

21 March 2001

U. S. Food & Drug Administration
Dockets Management Branch
5630 Fishers Lane, Room 1061
HFA-305
Rockville, MD 20852

5985 '01 MAR 23 P4:05

Re: Docket #00N-0989

Dear Sir or Madam:

Due to profound ethical issues, costs, public health risks, and the inability to adequately assess other alternatives, I urge the stoppage of all xenotransplantation clinical trials.

Because the pending proposal only brings gene therapy and xenotransplantation into compliance with similar information already released to the public by other governmental agencies, disclosure is still inadequate. Due to grave public health risks, this disclosure must include additional data (physicians, medical centers, etc.), and access by the public to all information except patient identities and trade secrets.

Moreover, the summary and dissemination of data cannot be left to the discretion of the sponsor; the FDA must assume this responsibility.

I am vigorously opposed to xenotransplantation.

Sincerely,

Larry L. Miller

Larry L. Miller
P.O. Box 11007
Brady Lake, Ohio 44211

00N-0989

C28